Literature DB >> 10194820

A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa.

B Knapp1, E Hundt, U Lenz, K D Hungerer, J Gabelsberger, H Domdey, E Mansouri, Y Li, B U von Specht.   

Abstract

Among the numerous targets which can be used for the development of vaccines against Pseudomonas aeruginosa we focused on the outer membrane proteins OprF and OprI. The C-terminal part of OprF from aa 190 to aa 350 was investigated for its conservation and its localization of B-cell epitopes. A hybrid protein which combines the protective epitopes of OprF and OprI was expressed in E. coli and was proven to be highly protective against an intraperitoneal challenge with P. aeruginosa by active immunization of immunocompromised mice as well as by passive immunization of SCID mice with specific antisera. A purification procedure of the N-terminal His-tagged hybrid antigen was established using immobilized-metal-affinity chromatography. To evaluate its safety and immunogenicity the recombinant protein was purified for the immunization of human volunteers. The OprF/OprI hybrid protein is considered to be a candidate for a vaccine against P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194820     DOI: 10.1016/s0264-410x(98)00420-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  The amino terminus of Pseudomonas aeruginosa outer membrane protein OprF forms channels in lipid bilayer membranes: correlation with a three-dimensional model.

Authors:  F S Brinkman; M Bains; R E Hancock
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

Review 2.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

Review 3.  Salmonella as a vaccine delivery vehicle.

Authors:  Kenneth L Roland; Karen E Brenneman
Journal:  Expert Rev Vaccines       Date:  2013-09       Impact factor: 5.217

4.  Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa.

Authors:  B M Price; D R Galloway; N R Baker; L B Gilleland; J Staczek; H E Gilleland
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 5.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

6.  RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF.

Authors:  A Krause; W Z Whu; J Qiu; D Wafadari; N R Hackett; A Sharma; R G Crystal; S Worgall
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

7.  A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

Authors:  Eric T Weimer; Haiping Lu; Nancy D Kock; Daniel J Wozniak; Steven B Mizel
Journal:  Infect Immun       Date:  2009-04-06       Impact factor: 3.441

8.  Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes.

Authors:  Géraldine Mayeux; Landry Gayet; Lavinia Liguori; Marine Odier; Donald K Martin; Sandra Cortès; Béatrice Schaack; Jean-Luc Lenormand
Journal:  Life Sci Alliance       Date:  2021-05-10

9.  Quest for Novel Preventive and Therapeutic Options Against Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Sidra Irum; Saadia Andleeb; Amjad Ali; Muhammad Ibrahim Rashid; Mahnoor Majid
Journal:  Int J Pept Res Ther       Date:  2021-08-09       Impact factor: 1.931

10.  Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.

Authors:  Ulrich Baumann; Kerstin Göcke; Britta Gewecke; Joachim Freihorst; Bernd Ulrich von Specht
Journal:  Respir Res       Date:  2007-08-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.